These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1924667)

  • 1. Predictors of therapeutic response to haloperidol in acute schizophrenia.
    McEvoy JP; Schooler NR; Wilson WH
    Psychopharmacol Bull; 1991; 27(2):97-101. PubMed ID: 1924667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients].
    Möller HJ; Scharl W; von Zerssen D
    Fortschr Neurol Psychiatr; 1985 Oct; 53(10):370-83. PubMed ID: 2866152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement.
    Bartkó G; Herczeg I; Békésy M
    J Clin Psychiatry; 1987 Sep; 48(9):363-5. PubMed ID: 3624207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
    McEvoy JP; Stiller RL; Farr R
    J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.
    Tuason VB
    J Clin Psychiatry; 1986 Mar; 47(3):126-9. PubMed ID: 3512535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
    Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF
    Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
    [No Abstract]   [Full Text] [Related]  

  • 9. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial improvement as a criterion for drug choice in acute schizophrenia.
    Klimke A; Klieser E; Lehmann E; Miele L
    Pharmacopsychiatry; 1993 Jan; 26(1):25-9. PubMed ID: 8104348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
    Stevens A; Mahal A; Gaertner HJ
    Pharmacopsychiatry; 1992 Sep; 25(5):218-23. PubMed ID: 1409866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance.
    Singh MM
    Dis Nerv Syst; 1976 Apr; 37(4):191-6. PubMed ID: 767080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
    Kuhs H; Folkerts H
    Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.
    Van Putten T; Marder SR; Mintz J
    Arch Gen Psychiatry; 1990 Aug; 47(8):754-8. PubMed ID: 2378546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.